排序方式: 共有44条查询结果,搜索用时 0 毫秒
31.
Faber E Pytlík R Slabý J Zapletalová J Kozák T Raida L Papajík T Zikesová E Maresová I Hamouzová M Indrák K Trnený M 《European journal of haematology》2006,77(6):493-500
OBJECTIVES: To explore the safety and effectiveness of the individually determined application granulocyte-colony stimulating factor (G-CSF) after autologous peripheral blood stem cell transplantation (ASCT). METHODS: The administration of G-CSF from day +5 (arm A) was compared in a randomised, controlled trial with delayed, individually determined administration (G-CSF started when WBC >or= 0.5 x 10(9)/L and ANC >or= 0.1 x 10(9)/L or at day +10; arm B), and with placebo (arm C). RESULTS: One hundred and six patients, median age 45 (range 21-64), all with malignant lymphoma treated with BEAM chemotherapy were analysed. A significant difference in the time to neutrophil engraftment and in the duration of neutropenia <0.5 x 10(9)/L and <1.0 x 10(9)/L was observed between the arms (P = 0.04-<0.0001) with a 1-d prolongation of the median durations in arm B in comparison with arm A but a 2-4-d prolongation in the placebo arm C in comparison with arm B. The median number and range of days to neutrophil engraftment >0.5 x 10(9)/L after graft re-infusion was 10 (9-14) in arm A; 11 (9-19) in arm B; and 14 (10-30) in arm C (P < 0.0001). Engraftment of platelets to >20 x 10(9)/L and >50 x 10(9)/L was significantly delayed in the arms using G-CSF in comparison with placebo (P = 0.04-0.002) without any increase in bleeding or in transfusion requirement. There was no difference in the incidence and duration of transplant-related complications and their treatment between the arms. CONCLUSIONS: Our study has confirmed the safety of individually determined administration of G-CSF. The optimal timing of G-CSF application after ASCT in patients with good-quality grafts is shortly before expected spontaneous engraftment. 相似文献
32.
Serum thymidine kinase 1 (TK1) is a sensitive marker of tumor cell proliferation. TK1 has been reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not yet been tested in large populations of patients with non-Hodgkin lymphoma. In this study, the prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma (FL). The TK1 level at the time of treatment initiation was shown to correlate with the clinical stage, Follicular Lymphoma International Prognostic Index (FLIPI) score, β(2)-microglobulin level, lactate dehydrogenase level and B symptoms. No correlation was found with FL grade or Ki-67 proliferation index. Cox regression analysis identified high TK1 levels (≥ 15I U/L) as a prognostic factor for overall survival (hazard ratio 2.91, p = 0.019) and progression-free survival (hazard ratio 1.94, p = 0.022) independent of FLIPI score variables. Thus, TK1 levels may help to refine risk assessment in the modern immunotherapy era. 相似文献
33.
High incidence of unbalanced chromosomal changes in mantle cell lymphoma detected by comparative genomic hybridization 总被引:6,自引:0,他引:6
Jarosová M Papajík T Holzerová M Dusek L Pikalová Z Lakomá I Raida L Faber E Divoká M Vlachová S Prekopová I Novosadová A Pospísilová H Indrák K 《Leukemia & lymphoma》2004,45(9):1835-1846
Comparative genomic hybridization (CGH) was carried out in 30 mantle cell lymphoma (MCL) patients at the time of diagnosis. CGH results were supported by conventional cytogenetics (CC), FISH, molecular genetic PCR methods and 2 patients were examined by array CGH. Using all cytogenetic, molecular cytogenetic and PCR methods, chromosomal changes were detected in 28 (93%) patients. Using CGH, unbalanced chromosomal changes were detected in 24 (80%) cases. The most frequent aberrations were losses of 1p (8 cases), 8p (10 cases), 9q (6 cases), 11q (11 cases), 13q (10 cases) and 17p (9 cases), and gains of chromosome 3 and 3q (12 cases) and 8q (7 cases). Total number of 60 gains and 116 losses were detected. The primary chromosomal change t(11;14) was detected using FISH and/or PCR in 20 (66.6%) patients, and in 9 of them, the breakpoint was determined using PCR in the major translocation cluster (MTC). The evaluation of the frequencies of CGH changes in groups of patients with and without t(11;14) revealed the differences only in losses 6q and 9q, which were only found in patient with t(11;14). An important result was obtained using array CGH method. In a patient without the primary t(11;14), the gain of CCND1 gene was found. Our results show high heterogeneity of the additional chromosomal changes in MCL cases, which involved specific chromosomal subregions. We did not confirm the importance of subdividing of MCL cases with and without t(11;14). Also, statistical significance in survival rates between both subgroups was not confirmed. 相似文献
34.
A group of 193 multiple myeloma (MM) patients consisting of cases treated only symptomatically (1959-63) or by nonsystematic monotherapy with Cyclophosphamide or Melphalan (1963-76) and of a subgroup given systematic polychemotherapy and intensive supportive treatment (1976-84) were evaluated for the practical applicability and prognostic relevance of three staging systems. The clinical staging system of Durie and Salmon and the quantitative system of Salmon and Wampler have proved in both subgroups of various periods and with different therapeutic approaches to be well applicable in the clinic allowing the patients to be divided into three prognostically different groups according to the size of the tumor mass. Merlini, Waldenstr?m and Jayakar's staging system has likewise shown relationship to prognosis though the patients could be divided only into two prognostically different groups. It is evident that a deeper knowledge of MM requires nowadays a more comprehensive, complex and prognostically more relevant classification system. 相似文献
35.
Isabel M.A. Brüggenwirth Marjolein van Reeven Indrė Vasiliauskaitė Danny van der Helm Bart van Hoek Alexander F. Schaapherder Ian P.J. Alwayn Aad P. van den Berg Vincent E. de Meijer Sarwa Darwish Murad Wojciech G. Polak Robert J. Porte 《Transplant international》2021,34(1):110-117
With the growing incidence of diabetes mellitus (DM), an increasing number of organ donors with DM can be expected. We sought to investigate the association between donor DM with early post-transplant outcomes. From a national cohort of adult liver transplant recipients (1996–2016), all recipients transplanted with a liver from a DM donor (n = 69) were matched 1:2 with recipients of livers from non-DM donors (n = 138). The primary end-point included early post-transplant outcome, such as the incidence of primary nonfunction (PNF), hepatic artery thrombosis (HAT), and 90-day graft survival. Cox regression analysis was used to analyze the impact of donor DM on graft failure. PNF was observed in 5.8% of grafts from DM donors versus 2.9% of non-DM donor grafts (P = 0.31). Recipients of grafts derived from DM donors had a higher incidence of HAT (8.7% vs. 2.2%, P = 0.03) and decreased 90-day graft survival (88.4% [70.9–91.1] vs. 96.4% [89.6–97.8], P = 0.03) compared to recipients of grafts from non-DM donors. The adjusted hazard ratio for donor DM on graft survival was 2.21 (1.08–4.53, P = 0.03). In conclusion, donor DM is associated with diminished outcome early after liver transplantation. The increased incidence of HAT after transplantation of livers from DM donors requires further research. 相似文献
36.
Tomáš Papajík Miroslav Mysliveček Zuzana Šedová Eva Buriánková Vít Procházka Pavel Koranda Luděk Raida Zuzana Kubová Miroslava Palová Ladislava Kučerová Patrik Flodr Jiří Jarkovský Ladislav Dušek Karel Indrák 《European journal of haematology》2011,86(1):32-37
Objectives: Positron emission tomography using 2‐[fluorine‐18]‐fluoro‐2‐deoxy‐d ‐glucose (18F‐FDG) is considered to be the most beneficial imaging method for staging patients with non‐Hodgkin’s lymphoma (NHL). The intensity of 18F‐FDG accumulation may be determined by calculating the so‐called standardised uptake value (SUV). The study aimed at assessing the benefit of SUVmax determination in staging 18F‐FDG PET/CT in untreated patients with NHL. Methods: One hundred and forty‐nine initial staging 18F‐FDG PET/CT scans performed in patients with NHL between January 2007 and August 2009 were assessed, and the SUVmax was determined. Results: The highest mean and median values of SUVmax were observed in patients with diffuse large B‐cell lymphoma (DLBCL), the lowest mean and median values were found in small lymphocytic lymphoma. The overlap in SUVmax < 10 between DLBCL and the other subgroups of NHL was very significant. Statistically, no correlation was found between the lactate dehydrogenase and SUVmax values. On the other hand, a correlation of the Ki‐67 proliferative index of tumour cells and SUVmax was revealed (r = 0.409, P < 0.001). The geometric mean of SUVmax in patients with Ki‐67 ≤ 60 and those with Ki‐67 > 60 was 8.8 and 14.3, respectively (P < 0.001). Conclusions: The results confirm that SUVmax is not beneficial for making a more precise diagnosis in most patients with NHL. Correlation of SUVmax with the Ki‐67 values suggests that SUVmax might have a prognostic values in NHL. 相似文献
37.
Faber E Friedecký D Mičová K Rožmanová S Divoká M Jarošová M Indrák K Adam T 《Annals of hematology》2012,91(6):923-929
Association of trough imatinib plasma levels (IPL) with cytogenetic or molecular response to treatment in patients with chronic
myeloid leukemia (CML) was repeatedly reported. We analyzed their value in the routine clinical setting in 131 patients with
chronic phase CML in whom imatinib was applied as first- or second-line treatment. A total of 1,118 measurements were obtained
by ultra-performance liquid chromatography–tandem mass spectrometry assay in patients treated with daily dose of imatinib
ranging from 100 to 800 mg. Samples were obtained from 1 to 96 h after drug ingestion. High inter (36%) and intraindividual
variability (9–33%) of IPL was observed. For analysis of correlation of IPL with treatment response, two sets of samples were
selected according to the European LeukemiaNet (ELN) criteria. The first set consisted of 241 samples taken 24 ± 2 h after
dosing in 54 patients, and the second one consisted of 329 samples taken 24 ± 4 h after imatinib ingestion in 84 patients.
In both sets, only patients treated with 400 mg imatinib once daily for at least 18 months were included. From multiple measurements
in individual patients, mean IPL were used. In both sets, we were not able to demonstrate a statistically significant correlation
between IPL and response to treatment according to the ELN. We believe that this was due to the differences in patients’ compliance,
leukemia biology, and other variables that are difficult to eliminate in the routine clinical practice. The use of IPL for
prognostic estimation in CML treatment outside the clinical trials is probably limited. 相似文献
38.
39.
40.
Faber E Mužík J Koza V Demečková E Voglová J Demitrovičová L Chudej J Markuljak I Cmunt E Kozák T Tóthová E Jarošová M Dušek L Indrák K 《European journal of haematology》2011,87(2):157-168
Background: Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres during 2000–2008. Patients and methods: Data reporting was retrospective in 2000–2004 and prospective from 2005 on. A total of 661 patients [301 women and 360 men; median age 51 (range, 15–83)] with Ph + CML were registered. The median follow‐up was 46.1 months (0–122.2). Results: Most patients were treated with first‐ (379; 57.3%) or second‐line (193; 29.2%) imatinib; some of the patients underwent allogeneic hematopoietic stem cell transplantation (AHSCT) (83; 12.6%), but 6.1% were treated with other modalities [40 patients; median age 66 (range, 32–83)]. The probability of overall survival (OS) at 5 years, according to Kaplan and Meier, was 88.9%, 77.5% and 68.7% for chronic‐phase patients treated with first‐line imatinib, second‐line imatinib and first‐line AHSCT, respectively, but only 25.2% for patients receiving other modalities. The OS was dependent on the disease phase and Sokal, Hasford and European group for blood and marrow transplantation (EBMT) risk scores (P < 0.001; each). Only 46.2% of deaths in patients treated with other modalities were attributable to CML. Elderly patients over 65 years achieved similar response rates and progression‐free survival to the younger ones. There was a trend for inferior results of AHSCT performed after the failure of imatinib (P = 0.075), probably as a result of differences in EBMT risk scores (P < 0.001). Conclusions: The ability to achieve results comparable to those of previous clinical studies in our CML cohort was influenced by centralised care. Decisions not to initiate imatinib or to delay AHSCT may have a negative impact on OS, but comorbidities may limit the treatment potential of imatinib in the elderly. 相似文献